caa a22 4500 388095032 CHVBK 20180307125302.0 cr unu---uuuuu 161130e199905 xx s 000 0 eng 10.1017/S1092852900007422 doi S1092852900007422 pii (NATIONALLICENCE)cambridge-10.1017/S1092852900007422 Montgomery Stuart A. Treatment of Obsessive-Compulsive Disorder [Elektronische Daten] [Stuart A. Montgomery] All the research to date implicates serotonin as the major neurotransmitter involved in obsessive-compulsive disorder (OCD). Much of the evidence has come from clinical treatment studies, which have shown the specific antiobsessional effect of drugs that are potent inhibitors of serotonin reuptake. Only the selective serotonin reuptake inhibitors (SSRIs) and the potent inhibitors of serotonin reuptake have been shown to be effective in treating patients with OCD. Serotonin receptor inhibitors and SSRIs have been thoroughly investigated in short- and long-term placebo-controlled studies and all have been found to be effective in OCD. Copyright © Cambridge University Press 1999 CNS Spectrums Cambridge University Press 4/S3(1999-05), 46-50 1092-8529 4:S3<46 1999 4 CNS https://doi.org/10.1017/S1092852900007422 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1017/S1092852900007422 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Montgomery Stuart A. NATIONALLICENCE 773 0- CNS Spectrums Cambridge University Press 4/S3(1999-05), 46-50 1092-8529 4:S3<46 1999 4 CNS CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-cambridge